- Home
- IBCP vs AUTL Comparison
IBCP vs AUTL Comparison
Compare IBCP & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBCP
- AUTL
- Stock Information
- Founded
- IBCP 1864
- AUTL 2014
- Country
- IBCP United States
- AUTL United Kingdom
- Employees
- IBCP N/A
- AUTL N/A
- Industry
- IBCP Major Banks
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IBCP Finance
- AUTL Health Care
- Exchange
- IBCP Nasdaq
- AUTL Nasdaq
- Market Cap
- IBCP 737.1M
- AUTL 590.8M
- IPO Year
- IBCP N/A
- AUTL 2018
- Fundamental
- Price
- IBCP $33.49
- AUTL $1.95
- Analyst Decision
- IBCP Hold
- AUTL Strong Buy
- Analyst Count
- IBCP 3
- AUTL 3
- Target Price
- IBCP $39.17
- AUTL $10.20
- AVG Volume (30 Days)
- IBCP 112.5K
- AUTL 1.2M
- Earning Date
- IBCP 01-23-2025
- AUTL 03-13-2025
- Dividend Yield
- IBCP 3.10%
- AUTL N/A
- EPS Growth
- IBCP 13.26
- AUTL N/A
- EPS
- IBCP 3.16
- AUTL N/A
- Revenue
- IBCP $218,142,000.00
- AUTL $10,091,000.00
- Revenue This Year
- IBCP N/A
- AUTL $851.88
- Revenue Next Year
- IBCP $6.56
- AUTL $220.57
- P/E Ratio
- IBCP $10.60
- AUTL N/A
- Revenue Growth
- IBCP 8.64
- AUTL 82.71
- 52 Week Low
- IBCP $22.53
- AUTL $1.87
- 52 Week High
- IBCP $40.32
- AUTL $6.63
- Technical
- Relative Strength Index (RSI)
- IBCP 35.19
- AUTL 37.49
- Support Level
- IBCP $34.32
- AUTL $1.92
- Resistance Level
- IBCP $36.17
- AUTL $2.15
- Average True Range (ATR)
- IBCP 1.04
- AUTL 0.12
- MACD
- IBCP -0.26
- AUTL 0.01
- Stochastic Oscillator
- IBCP 0.00
- AUTL 22.22
About IBCP Independent Bank Corporation
Independent Bank Corp (Ionia MI) operates as a commercial bank. It offers a broad range of banking services to individuals and businesses, including checking and savings accounts, commercial lending, direct and indirect consumer financing, mortgage lending, and safe deposit box services. It also provides internet and mobile banking capabilities to its customers.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.